EF Hutton Initiates Coverage On CollPlant Biotechnologies with Buy Rating, Announces Price Target of $14
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy rating and set a price target of $14.
August 05, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on CollPlant Biotechnologies with a Buy rating and set a price target of $14.
The initiation of coverage with a Buy rating and a specific price target of $14 by EF Hutton is likely to positively influence investor sentiment and drive short-term price appreciation for CLGN.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100